SG11201805092WA - Cortistatin analogs and uses thereof - Google Patents
Cortistatin analogs and uses thereofInfo
- Publication number
- SG11201805092WA SG11201805092WA SG11201805092WA SG11201805092WA SG11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- mpk
- quincy
- president
- cambridge
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387246P | 2015-12-23 | 2015-12-23 | |
| US201662297494P | 2016-02-19 | 2016-02-19 | |
| PCT/US2016/068125 WO2017112815A1 (en) | 2015-12-23 | 2016-12-21 | Cortistatin analogs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805092WA true SG11201805092WA (en) | 2018-07-30 |
Family
ID=59091204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805092WA SG11201805092WA (en) | 2015-12-23 | 2016-12-21 | Cortistatin analogs and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20180298024A1 (pt) |
| EP (1) | EP3394072A4 (pt) |
| JP (1) | JP2019508368A (pt) |
| KR (1) | KR20180095051A (pt) |
| CN (1) | CN108699085A (pt) |
| AU (1) | AU2016377678A1 (pt) |
| BR (1) | BR112018012647A2 (pt) |
| CA (1) | CA3009324A1 (pt) |
| CL (1) | CL2018001733A1 (pt) |
| CO (1) | CO2018007535A2 (pt) |
| EA (1) | EA201891511A1 (pt) |
| IL (1) | IL260123A (pt) |
| MX (1) | MX2018007804A (pt) |
| PH (1) | PH12018501351A1 (pt) |
| RU (1) | RU2018126984A (pt) |
| SG (1) | SG11201805092WA (pt) |
| WO (1) | WO2017112815A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221048A1 (es) | 2015-07-02 | 2022-06-30 | Hoffmann La Roche | Lactamas biciclicas como inhibidores de rip1 cinasa |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CN112074519A (zh) | 2018-04-20 | 2020-12-11 | 豪夫迈·罗氏有限公司 | 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征（ibs）的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物 |
| JP2022515705A (ja) * | 2018-11-01 | 2022-02-22 | サイロス ファーマシューティカルズ， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の非共有結合性阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642766B2 (en) * | 2008-05-05 | 2014-02-04 | Ryan A. Shenvi | Synthesis of (+) cortistatin A and related compounds |
| WO2010024930A2 (en) * | 2008-08-28 | 2010-03-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses therof |
| US20130217014A1 (en) * | 2012-02-17 | 2013-08-22 | Genentech, Inc. | Methods of using cdk8 antagonists |
| WO2014123900A1 (en) * | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
| CR20160291A (es) * | 2013-12-24 | 2017-02-24 | Harvard College | Análogos de cortistatina y síntesis y usos de los mismos |
-
2016
- 2016-12-21 JP JP2018532374A patent/JP2019508368A/ja active Pending
- 2016-12-21 CN CN201680082319.0A patent/CN108699085A/zh active Pending
- 2016-12-21 KR KR1020187020634A patent/KR20180095051A/ko unknown
- 2016-12-21 RU RU2018126984A patent/RU2018126984A/ru not_active Application Discontinuation
- 2016-12-21 AU AU2016377678A patent/AU2016377678A1/en not_active Abandoned
- 2016-12-21 EP EP16880055.5A patent/EP3394072A4/en not_active Withdrawn
- 2016-12-21 MX MX2018007804A patent/MX2018007804A/es unknown
- 2016-12-21 SG SG11201805092WA patent/SG11201805092WA/en unknown
- 2016-12-21 WO PCT/US2016/068125 patent/WO2017112815A1/en active Application Filing
- 2016-12-21 CA CA3009324A patent/CA3009324A1/en not_active Abandoned
- 2016-12-21 EA EA201891511A patent/EA201891511A1/ru unknown
- 2016-12-21 BR BR112018012647A patent/BR112018012647A2/pt not_active Application Discontinuation
-
2018
- 2018-06-18 IL IL260123A patent/IL260123A/en unknown
- 2018-06-22 US US16/016,199 patent/US20180298024A1/en not_active Abandoned
- 2018-06-22 CL CL2018001733A patent/CL2018001733A1/es unknown
- 2018-06-22 PH PH12018501351A patent/PH12018501351A1/en unknown
- 2018-07-18 CO CONC2018/0007535A patent/CO2018007535A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017112815A1 (en) | 2017-06-29 |
| AU2016377678A1 (en) | 2018-07-12 |
| EP3394072A1 (en) | 2018-10-31 |
| MX2018007804A (es) | 2019-07-04 |
| EA201891511A1 (ru) | 2018-12-28 |
| JP2019508368A (ja) | 2019-03-28 |
| US20180298024A1 (en) | 2018-10-18 |
| PH12018501351A1 (en) | 2019-02-27 |
| KR20180095051A (ko) | 2018-08-24 |
| RU2018126984A (ru) | 2020-01-23 |
| CN108699085A (zh) | 2018-10-23 |
| EP3394072A4 (en) | 2019-05-29 |
| BR112018012647A2 (pt) | 2018-12-04 |
| CL2018001733A1 (es) | 2018-11-09 |
| IL260123A (en) | 2018-07-31 |
| CO2018007535A2 (es) | 2018-07-31 |
| CA3009324A1 (en) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805092WA (en) | Cortistatin analogs and uses thereof | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201804363UA (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
| SG11201407268SA (en) | Nuclear transport modulators and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201805001UA (en) | Method of treating influenza a |